Safety aspects of HIV-protease inhibitors
Veiligheids aspecten van HIV-proteaseremmers
The objectives of this thesis were to provide more insight into the risk and risk factors of adverse drug reactions associated with HIV-protease inhibitor treatment under non-experimental everyday circumstances. By recognition of risk factors, patients at risk can be identified beforehand and risk management can be targeted more efficiently, hence ultimately improving the safety of HIV-protease inhibitor treatment. In the studies presented in this thesis we applied multiple research strategies. tn which the nationwide ATHENA cohort played a central role.
|Keywords||AIDS, ATHENA cohort, HIV, HIV-protease inhibitors, adverse effects, antiretroviral therapy, pharmacology|
|Promotor||B.H.Ch. Stricker (Bruno)|
|Publisher||Erasmus University Rotterdam|
|Sponsor||The publication of this thesis was financially supported by Abbott BV, Boehringer Ingelheim BV, Bristol-Myers Squibb BV, Glaxo Smith Kline BV, Merck Sharp & Dohme BV and Roche Pharmaceuticals BV.|
Dieleman, J.P. (2002, June 12). Safety aspects of HIV-protease inhibitors. Erasmus University Rotterdam. Retrieved from http://hdl.handle.net/1765/31921